Enhance your patent search with AI. Try the FREE AI-powered tool

Published by: Parola Analytics

a medical technician using the microscope

Apollo unit files patent lawsuit against Indian generic drugmaker

Apollo Global Management’s wholly-owned unit, Covis Pharma, alleged that Indian pharmaceutical company Eugia and its parent Aurobindo infringed upon two of its patents (US10471075B1 and US9844558B1). Both patents concern its Makena product, an injectable treatment that is used to reduce the risk of premature birth.

Read More »
drug tablets

Drug patent listing and exclusivity clarified in new US bill

The Orange Book Transparency Act of 2020 (H.R. 1503) was signed into law last January 5, 2021. The Act updates regulations of the US Food and Drug Administration concerning the Approved Drug Products with Therapeutic Equivalence Evaluations (more commonly known as the Orange Book) which contains publicly available patent and exclusivity information, particularly on approved and available generic drugs.

Read More »
bitcoin coin closeup

Betting with bitcoin: Gambling giant granted crypto payment patent

International Game Technology (IGT) has patented a technology that uses cryptocurrencies as a form of payment in casinos. The USPTO granted IGT a patent last January 5 for a system that allows cryptocurrency funds to be transferred to a “gaming establishment account” from a player’s external crypto account. This allows users to transfer cryptocurrencies like Bitcoin from their private wallets to virtual wallets linked to casino accounts with the use of their phones. 

Read More »
IBM office

USPTO reports dramatic growth in AI patents; IBM, Microsoft and Google top patent owner list

Ericsson announced in December that it filed a lawsuit against Samsung in the US for allegedly violating its contractual commitments related to patent licences and royalty payments. The patent dispute may negatively affect the Swedish company’s operating income by SEK 1- 1.5 billion ($118-$177 million) per quarter starting from 2021 due to the delay of royalty payments and the potential costs of litigation.

Read More »

Subscribe to our newsletter

  • Questions? Check our privacy policy.
  • This field is for validation purposes and should be left unchanged.

Patent and IP updates straight to your inbox

Sign up now to receive monthly patent news, analysis and free insight reports.

We don’t spam, we promise.


1. Parola Analytics and Avontis are distinct entities and operate independently. Any references to Avontis or its services do not constitute a legal partnership. 

2. Parola Analytics does not provide legal services. Our services are limited to research and technical analysis. Any information provided by Parola Analytics should not be construed as legal advice.